[NMusers] Post-doc Position in Cancer Reserach Center of Toulouse, France

From: Chatelut Etienne <Chatelut.Etienne_at_iuct-oncopole.fr>
Date: Wed, 1 Jun 2016 13:26:31 +0000

Position: Post-doctoral Associate in Pharmacometrics



Team < Dose individualisation in anticancer drugs > which is a part of the =
Cancer Research Center of Toulouse (CRCT) INSERM UMR1037, Toulouse Universi=
ty



Position description: a one year (renewable), full time, post-doctoral asso=
ciate position in clinical pharmacokinetics-pharmacodynamics (PK/PD) and qu=
antitative systems pharmacology (QSP).

This position focuses on population PK/PD analysis in the area of anticance=
r therapies. The Post-doc fellow would be invited to get involved in the de=
sign, implementation and analysis of clinical trials for drugs developed in=
 Oncology and Haematology.



Qualifications required: A solid experience of PK modelling software such a=
s NONMEM, Monolix, R... would be required. The researcher would collaborat=
e on different projects with the other members of our multidisciplinary tea=
m (pharmacology, pharmacogenetics, biostatistics, analytical chemistry). T=
he researcher will have access to all the platforms and administrative faci=
lities within the CRCT and will supervise students for master degree placem=
ents, or doctoral positions.

How to apply: Please send CV, a letter of interest, and the names and email=
 addresses of two referees to Etienne Chatelut (Team leader) chatelut.eti=
enne_at_iuct-oncopole.fr.



CRCT Overview: The brand new 'Oncopole' campus, based in Toulouse (South We=
st of France), gathers academic, scientific, medical, clinical, technologic=
al, and pharmaceutical research on cancer. Its missions are to improve fund=
amental knowledge on all aspects of cancer biology and to provide patients =
with rapid access to innovative and individualized treatments. The main act=
ors of Toulouse Oncopole are: The Cancer Research Center of Toulouse (CRCT)=
, a public research laboratory supported by Inserm, University Toulouse III=
-Paul Sabatier and CNRS; The Institut Universitaire du Cancer de Toulouse-O=
ncopole (IUCT-O), a cancer care center. Oncopole is the place where clinici=
ans from IUCT-O, translational research groups, and basic scientists from C=
RCT have the ideal environment to develop their projects.



The following publications give an idea of our research area:

- Schmitt A et al: Factors for hematopoietic toxicity of carbo=
platin: refining the targeting of carboplatin systemic exposure. J Clin Onc=
ol 2010;28:4568-4574 ;

- White-Koning M et al: Population analysis of erlotinib in ad=
ults and children reveals pharmacokinetic characteristics as the main facto=
r explaining tolerance particularities in children. Clin Cancer Res 2011;17=
:4862-4871

- Thomas F et al : Genotyping of a family with a novel deleter=
ious DPYD mutation supports the pretherapeutic screening of DPD deficiency =
with dihydrouracil/uracil ratio. Clin Pharmacol Ther.2016 Feb;99(2):235-42.=
Chalret du Rieu Q et al: Pharmacokinetic/Pharmacodynamic modeling of abexin=
ostat-induced thrombocytopenia across different patient populations: applic=
ation for the determination of the maximum tolerated doses in both lymphoma=
 and solid tumour patients. Invest New Drugs. 2014;32:985-94.

- Imbs DC et al: Pharmacokinetics of pazopanib administered in=
 combination with bevacizumab. Cancer Chemother Pharmacol 2014;73:1189-96.


Received on Wed Jun 01 2016 - 09:26:31 EDT

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:50:48 EDT